India · Delayed Price · Currency is INR Divi's Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw strong revenue and profit growth, driven by custom synthesis and stable generics volumes, despite ongoing pricing pressures. Backward integration, capacity expansion, and a robust export mix supported performance, with major custom synthesis projects set for commercialization in late 2027.
-
Q2 FY2026 saw 17% YoY revenue growth, record custom synthesis revenue, and stable generics volumes despite pricing pressure. CapEx will exceed INR 2,000 crore for FY2026, with major investments in capacity and technology. Gross margin remains stable at ~60% as product mix shifts toward custom synthesis.
-
Q1 FY26 saw strong revenue and profit growth, driven by robust custom synthesis and operational resilience despite ongoing pricing pressures in generics. Major CapEx is underway, with new facilities and advanced capabilities positioning for future growth.
Fiscal Year 2025
-
FY25 saw strong revenue and profit growth, driven by robust custom synthesis momentum, stable generics, and expanding peptide capabilities. Major long-term contracts and capacity investments position the company for double-digit growth, with new project revenues expected from late 2026.
-
Q3 FY25 saw strong revenue and profit growth, driven by custom synthesis and generics, with exports at 87% of sales. Kakinada Unit Three's commissioning boosts capacity, while double-digit growth and stable margins are targeted amid easing logistics and price pressures.
-
Q2 FY25 saw strong revenue and profit growth, driven by custom synthesis demand and resilient generic volumes despite pricing pressure. Investments in peptide and contrast media capabilities, along with the upcoming Unit 3 facility, position the business for future growth.
-
Q1 FY25 revenue grew 18% YoY to INR 2,197 crores, with strong custom synthesis and stable generics performance. Expansion projects and peptide investments are progressing, while API pricing pressure persists but is expected to stabilize.